Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
Keyword(s):
Phase Ii
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. e16016-e16016
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):